Longwood-Founded Immunitas Therapeutics Launches with $39 Million to Advance Lead Programs to Human Efficacy Studies Based on a Unique Immunology-Focused Drug Development Platform November 21, 2019
MPM and Longwood-backed Werewolf Therapeutics Grabs $56 Million to Take Tumors by Night November 20, 2019
Werewolf Therapeutics Launches with $56M Series A Financing to Develop Transformative Immuno-Stimulatory Cancer Medicines November 20, 2019
Axial Therapeutics Announces Completion of Enrollment in Phase 1b/2a Clinical Trial Evaluating AB-2004 in Patients with Autism Spectrum Disorder November 18, 2019
